Open access
Nov 2026
Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study
Findings support individualized adjuvant chemotherapy selection and warrant confirmation in larger cohorts with longer follow-up, particularly regarding the incremental benefit of anthracyclines.
Perihan Perkin, D. Sarikaya, H. Karakaş et al.
· Journal of Clinical Medicine · 0 citations